What is DoxTree?

The Value Proposition

DoxTree is a doctor-patient focused, secure and compliant "walled garden" social technology platform (patented). Both doctor-to-doctor secure and compliant connections AND doctor-to-patient secure and compliant connections including powerful workflow, are a part of the DoxTree medical-social platform. Curated by Doctors/staff and populated by their patients, DoxTree is a medical-social technology platform that enables doctors to provide better health care, increase revenues and save time.

Try It!

Invite Only [Beta]

Click here to receive your [Beta] invite!

Follow Us

 
Blog

Government Poised To Provide A Huge Boost To Healthtech Startups…

posted yesterday
Regina Holliday - Meaningful Use

Editor’s note: This guest post was written by Dave Chase, the CEO of Avado.com, a patient portal and relationship management company that was a TechCrunch Disrupt finalist. Previously he was a management consultant for Accenture’s healthcare practice and founder of Microsoft’s Health platform business. You can follow him on Twitter @chasedave.

Currently, the federal government is poised to level the playing field for healthtech startups. An unprecedented wave of innovative healthtech startups has been developing over the last few years. You can see them at conferences such asHealth 2.0TechCrunch DisruptTEDMED and demo day events that Blueprint HealthHealthboxRock Health andStartUp Health host. Nonetheless, the health sector may be the single most challenging arena for startups.

MORE:   http://tcrn.ch/HLSdfF

 

FDAs Social-Media Guidelines Befuddle Big Pharma | Digital – Advertising Age

FDAs Social-Media Guidelines Befuddle Big Pharma | Digital – Advertising Age.

 

Launched!

Launched! Nice work DoxTree team!! Thanks...

 

Pfizer social media response guard rails

pfizer-social-media-response-guard-rails-dec-10-2.jpg 960×720.

 

 

Is Social Business the Same as Social Media? – Forbes

Is Social Business the Same as Social Media? – Forbes.

 

Social 2.0

DoxTree is SOCIAL 2.0! The practical, useful application of social technology in MEANINGFUL places throughout our daily lives.

 

Doctors want to “Tweet”…

But not on Twitter!

 

Hard Truths – NY Times

January 21, 2012
I Disclose … Nothing
By ELISABETH ROSENTHAL
IN New York and a growing number of American cities, diners are encountering sanitary grades in restaurants’ windows — A, B or C. That system is an example of helpful disclosure, researchers say: information that is simple and comprehensible, important to recipients and easily acted upon. I recently chose between outwardly identical Japanese noodle shops on East Ninth Street in Manhattan based on the system, walking into the A rather than the B.

But as greater disclosure has become the go-to solution for a wide range of problems — from unethical campaign financing to rising corporate carbon emissions — it has often delivered lackluster results, researchers say.

Just last week, the Obama administration announced plans to require drug companies to disclose a wide variety of payments and gifts to doctors, from speaking fees to the purchase of breakfasts for office staffs, in the hope of reducing commercial influence on prescribing practices. President Obama has promised to run the most open, transparent administration in history. But is more disclosure the solution?

If recent history serves as a guide, disclosure laws — meant to elucidate — do not necessarily lead to greater transparency or prevent the things they were meant to deter. Every holder of a subprime mortgage that is now underwater once signed an elaborate disclosure statement required by the Truth in Lending Act describing precisely the risky terms of their loan. Likewise, “super PACs” in the presidential campaign are technically compliant with financial disclosure laws, but have so far proved successful at hiding many of the sources of their money.

Everyone agrees that openness is a virtue in a democracy. So what is going wrong?

One fundamental problem is that disclosure requirements merely get information onto the table, but themselves demand no further action. According to political theory, disclosure is both a citizen’s right and a tool to ensure good government and consumer protection, because it provides information that leads to informed decisions. Instead, disclosure has often become an endpoint in the chain of responsibility, an act of compliance with the letter of the law rather than the spirit of transparency.

“In the beginning, disclosure was a means to an end, and now it’s often an end in itself,” said Kevin P. Weinfurt, professor of psychiatry and behavioral science at Duke University. “People think, ‘If we’ve disclosed we’ve fulfilled our responsibilities.’ ”

Indeed, disclosure has taken on the gestalt of confession: Dump the information and be absolved of further moral or legal responsibility. How did car-crazy cities like Los Angeles and Phoenix earn an A+ in a study by the Roberts Environmental Center at Claremont McKenna College? By being superb at disclosing, not controlling, emissions. Clyde Wilcox, a political scientist at Georgetown University, said: “Disclosure by itself is not the solution to any problem. It’s a path to earn trust. But just saying things is not enough, unless you also do something.”

Part of the problem is that the goals of disclosure are often unclear, said Dr. Weinfurt, who has studied disclosure in medicine. “We want the information, but often no one knows exactly what to do with the information once they get it.”

For example, how should one respond to the government disclosure letters sent to homes in the United States with information about local water quality, containing lists of chemical compounds in parts per million? And what was the appropriate reaction to the Homeland Security Department’s recently abandoned program to disclose risk assessments with color-coded warnings at airports ranging from safe green to “severe” red?

Unlike the restaurant-grading system, such threat-level disclosure “is ineffective because there’s no way to act on it,” said Archon Fung, co-founder of the Transparency Policy Project at the Harvard Kennedy School.

Many disclosure programs today cloud rather than clarify a particular situation. As disclosure statements have become more numerous and more complicated, “consumers just ignore them or don’t understand what they say,” said Jeff Sovern, an expert in consumer law at St. John’s University.

To illustrate how few people actually read its terms and conditions disclosure, the online retailer Gamestation, on April Fools’ Day 2010, replaced the usual text with what it called an “immortal soul clause,” which read: “By placing an order via this Web site on the first day of the fourth month of the year 2010 anno Domini, you agree to grant us a non-transferable option to claim, for now and forever more, your immortal soul.” Eager to get on with their online purchase, 88 percent of customers clicked the box to sell their souls. (The 12 percent who opted out were rewarded with a cash credit for their diligence.)

But information overload, not consumer laziness, is often to blame, Professor Sovern says. At real estate closings, in less than an hour, buyers sign reams of paper they are seeing for the first time — including the mortgage disclosure form — to take ownership of a residence they’ve already chosen. Everyone signs, Professor Sovern says, adding: “Predatory lenders try to distract people with lots of paper. I think disclosures sometimes create the illusion of consumer protection — enabling legislators to claim credit for consumer protection, without the reality.”

When the Food and Drug Administration in the 1990s first mandated that drug makers list medicines’ side effects in order to advertise prescription drugs, there was a firestorm of protest from the industry. Now the litany of side effects that follows every promotion is so mind-numbing — drowsiness, insomnia, loss of appetite, weight gain — as to make the message meaningless.

Extolling the virtues of transparency, Supreme Court Justice Louis D. Brandeis famously wrote in 1913 that “sunlight is said to be the best of disinfectants.” But in the cynical world, companies and political groups often deflect that light or diffuse it into 1,000 incomprehensible components.

While regulators and consumers see disclosure as a way to improve transparency, companies often regard it as a risk-management strategy. “Often the goal of disclosure is to reduce or eliminate the legal risk,” Dr. Weinfurt said. “It is so they can say, ‘Hey we told you so.’ ”

Organizations often go to great lengths to avoid meaningful disclosure. This year, some Republican super PACs exploited Federal Election Commission loopholes that allow them to delay releasing donor names. By re-registering or changing their status, they have effectively reset the disclosure timetable, postponing release until Jan. 31, after what may well prove the race-defining primaries.

“Where we are in campaign finance is the worst of all worlds — disclosure’s only partial, and you can’t really tell what’s not being disclosed,” said Professor Wilcox of Georgetown. “It allows people to wave a wand and say, ‘I am clean.’ But it’s hard to tell where money comes from. I’m not sure if this kind of imperfect disclosure helps anyone.” (On the other hand, some argue that disclosure may deter donors fearful of political retaliation, from powerful incumbents, for example.)

Lobbying disclosure — centered on a federal database where lobbyists must register and report their clients — is “in better shape,” Professor Wilcox said, although some argue that the formalization of lobbying disclosure procedures has helped normalize unethical influence peddling. It promotes “the expectation that there will be relationships,” Dr. Weinfurt said.

Despite reservations about many current disclosure practices, experts are stalwart defenders of the underlying principle. The very availability of such information allows scholars, journalists and regulators to uncover wrongdoing, Professor Fung said.

But how hard that can be is underlined by the elaborate procedures that medical journals have developed to screen potential authors for conflicting financial ties to industry. In the 1980s, The New England Journal of Medicine began to ask researchers who contributed articles to disclose outside financial interests like consulting arrangements or stock ownership. Today, potential authors submit long disclosure statements that editors dissect like private investigators before assigning an article. “We wrestle with this all the time and turn down many people who could write good reviews,” said Jeffrey M. Drazen, the editor of the journal.

The journal’s editors have redoubled their efforts after “being burned” a few years ago, when they published a lung cancer study financed by a foundation that turned out to be a front for tobacco industry money, Dr. Drazen said, adding: “We spend a lot of time going through disclosure forms. I’ll think: ‘Gates Foundation, I know that. Howard Hughes, I know. But I don’t know this one.’ I need to know who supports them, do they have an agenda, do they make a product that is related?”

So perhaps the answer is not just more information. “I don’t necessarily think that more is better,” said Professor Fung of Harvard. “I’d like to see an effort toward prioritizing what information is really important and then some effort in providing the data in a way that is simple and effective.”

In light of recent experience, will the Obama plan to require drug makers to disclose payments to doctors and hospitals be useful and make a difference? Some companies already disclose part of this information. Merck, for example, released a list of doctors whom it paid to give promotional lectures for its drugs in the second half of 2009. Though the list does not include other kinds of consulting or payments, it nonetheless goes on, in fine print, for 72 pages.

Likewise, one of the president’s favorite agencies, the Consumer Financial Protection Bureau, is designing new, simplified mortgage disclosure forms. They are up on its Web site for your consideration. But it warns that the proposed “simplified” forms, which span five or six pages, are not so simple as might be expected — because of more newly required disclosures.

Elisabeth Rosenthal is a reporter and blogger on environmental issues for The New York Times.

 

Sunshine Act – DoxTree solves this too!

The Sunshine Act: The Good, the Bad, and the Ugly

October 14, 2011 · Leave a comment

Industry Insights from Paul Meade, M. Sc, MPH

The Sunshine Act is on the horizon, and all we know for certain is that things will be different. Will the changes be good, bad, or ugly for healthcare and the biopharmaceutical industry? Well, a bit of all three. But it is a bit like the Y2K scare, or the coming of the end of the world in December 2012 predicted by the Mayans—people in healthcare and biopharma are on alert, and no one really knows for certain how this will all play out.

Let’s start with the good, since there will be greater transparency in the interactions between manufacturers and physicians. The intended outcomes will be greater standards of remuneration for services rendered by healthcare professionals to various manufacturers, some defined threshold limit of activities (type and quantity) deemed permissible by institutions for their affiliated physicians, and a greater sense of awareness of the interactions between healthcare professionals and manufacturers, presumably by a concerned public.

With regard to the first outcome, it is hoped that some kind of industry standard for Fair Market Value will be established for the activities physicians are often engaged in when dealing with manufacturers. It will likely serve to “level the playing field,” so some manufacturers will not pay excessively for a given activity, such as consultative services. As for the second outcome, a small number of highly-regarded and globally-recognized experts are heavily involved in activities with several manufacturers in their field of expertise, and their academic institutions are often unaware to the extent of this involvement. So the institutions may place limits on the total amount of remuneration or total number of certain activities permitted by their healthcare professionals (some institutions have already done these things). These overall limits are set almost arbitrarily without regard to the types of activities, or evaluating the merits of one activity over another one. Perhaps these institutions will now begin to place a bit more scrutiny in the types of activities their physicians are engaged in with manufacturers, and take into account their overall qualifications and global stature in the medical community.

The third outcome relates to a concerned public, which may be the biggest unknown facing those dealing with the Sunshine Act. Is there really public concern over the interactions between physicians and manufacturers? I believe that this concern is real only to the extent that such interactions may be perceived as compromising the objectivity and integrity of those physicians, and less real as to their degree of compensation for such services.

Now, let’s talk about the bad. Manufacturers have to report all expenditures over $10 that they pay to a physician or institution, even if it is for a sandwich for lunch. If there are any mathematicians in the house, can you attempt to calculate how many transactions will need to be reported between 800,000 physicians in the United States and over 300 manufacturers over a 12-month period? It’s a number likely to be in the hundreds of millions. So here are two questions: firs, who will read all of this data, and second, who pays for all this? I sure hope the answers are not no one and all of us, respectively!

If physicians fear too many repercussions from both the institutions they work in, as well as from the patients they serve, might they just cease to work with any manufacturer at all? No more clinical studies, no more conferences, no more research publications, and no more scientific advisory board meetings associated in any way with a manufacturer. This could be bad! There has been a long-standing working relationship between the medical profession and manufacturers that has served to bring innovation and discovery to the field of healthcare in the United States. Could legislation designed to bring greater transparency to such interactions have such grave unintended consequences that this entire symbiotic relationship could be thrown into chaos? Could the United States lose its reputation and competitive advantage across the globe for innovation in healthcare simply to meet the demands to report all financial transactions between physicians and manufacturers? And for whom and for what ultimate purpose? This could get really bad very soon!

Finally, let’s face the ugly. Sometimes the best plans have such dire unintended consequences that the end results never even come close to outweighing the benefits. If the Sunshine Act results in a sort of “witch hunt” by the media to expose a few physicians they deem interacting excessively with certain manufacturers, then this is a very ugly outcome, indeed. If great reputations become destroyed by an over-zealot press trying to bring a “story” to their readers, then this entire effort to achieve greater transparency will fall flat on its face. To quote from MacBeth, “It is a tale, full of sound and fury….signifying nothing.” And that would be ugly!

 

Are you kidding? This is it?

From the Digital Health Coalition…

Social Guiding Principles Project
As part of the DHC member meeting in NYC on February 6, 2012 the coalition will introduce the Social Guiding Principles (and related projects). We are seeking continued feedback during the comment period and look forward to working with DHC members, industry thought leaders, and patients to expand on the initial framework in the coming weeks and months.
Social Media and User-generated Health and Medical Content:
Guiding Principles and Best Practices for Companies and Users
1) Regulated healthcare companies should endeavor to participate in social media as a means to promote public health, improve patient outcomes and facilitate productive patient/physician relationships.
2) Regulated healthcare companies are not responsible for user-generated content online that they do not control. Regulated healthcare companies are deemed to “control” health and medical content if (i) it owns such health and medical content and has material editorial authority or (ii) it paid for the creation of such content and has material editorial authority over such content.
3) Regulated healthcare companies have a responsibility to report adverse events they become aware of. Regulated healthcare companies should follow the existing adverse event reporting rules in place at the FDA.
4) Employees of regulated healthcare companies should disclose their material company relationship when posting comments/content or engaging in an online conversation relating to a company product or relevant healthcare issue.
5) Regulated healthcare companies should endeavor to respond to questions on sites they control within a reasonable period of time, and to implement reasonable measures to enable timely responses to crisis and emergency situations.
6) Regulated healthcare companies should endeavor to make reasonable efforts to correct misinformation that is factually incorrect.
7) Regulated healthcare companies should endeavor to appoint employee(s) tasked with the role of “patient liaison” focused on representing the best interests of the patient online.